Goldman Sachs and Morgan Stanley are advising BD’s acquisition of Edwards Lifesciences’ Critical Care Product Group for $4.2 billion.
This move enhances BD’s portfolio with advanced patient monitoring technologies and AI-enabled clinical decision tools. BD, a global medical technology leader, has agreed to buy the Critical Care division from Edwards Lifesciences. Specializing in advanced monitoring solutions, this division includes innovations like
You must be logged in to post a comment.